Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Therapy Name||Pegylated liposomal doxorubicin + Peposertib|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Pegylated liposomal doxorubicin||Doxil||ATI-0918|CAELYX|liposomal doxorubicin||Chemotherapy - Anthracycline 13||Doxil (pegylated liposomal doxorubicin) comprises the anthracyline doxorubicin, which intercalates into DNA and disrupts DNA replication, encapsulated in a liposome, which improves tumor penetration and decreases toxicity (NCI Drug Dictionary), and is FDA approved for ovarian cancer, AIDS-related Kaposi's sarcoma, and multiple myeloma (FDA.gov).|
|Peposertib||M3814|M-3814|Nedisertib|MSC2490484A||DNA_PK Inhibitor 9||Peposertib (MSC2490484A) is a DNA-dependent protein kinase (DNA-PK) inhibitor that blocks DNA damage repair, which may lead to antitumor activity by sensitizing cancer cells to radiation and agents that induce DNA double strand breaks (PMID: 32220971).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|
|NCT05711615||Phase I||Pegylated liposomal doxorubicin + Peposertib||Testing Low-Dose Common Chemotherapy (Liposomal Doxorubicin) in Combination With an Anti-Cancer Drug, Peposertib, in Advanced Sarcoma||Suspended||USA||0|
|NCT04092270||Phase I||Pegylated liposomal doxorubicin + Peposertib||A Study Combining the M3814 Pill With Standard Chemotherapy in Patients With Ovarian Cancer With an Expansion in High Grade Serous Ovarian Cancer and Low Grade Serous Ovarian Cancer Patients||Recruiting||USA||0|